Cargando…
T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology
Gene-engineered T-cell therapies have the potential to revolutionize the treatment of cancer. These therapies have shown exceptional clinical efficacy specifically in the field of B-cell malignancies and the first products (Kymriah™ and Yescarta™) have recently been approved in the United States for...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843031/ https://www.ncbi.nlm.nih.gov/pubmed/29471776 http://dx.doi.org/10.1177/0192623317752101 |